RT Journal Article
SR Electronic
T1 Response to PD1 inhibition in conventional chondrosarcoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 94
DO 10.1186/s40425-018-0413-z
VO 6
IS 1
A1 Michael J. Wagner
A1 Robert W. Ricciotti
A1 Jose Mantilla
A1 Elizabeth T. Loggers
A1 Seth M. Pollack
A1 Lee D. Cranmer
YR 2018
UL http://jitc.bmj.com/content/6/1/94.abstract
AB Background Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy.Case presentation We describe a 67-year-old man with metastatic conventional chondrosarcoma who was treated with nivolumab. Treatment was discontinued after restaging showed increased tumor burden, which later proved to be pseudoprogression. The patient restarted nivolumab and continues to have a near complete response.Conclusion Conventional chondrosarcoma may be sensitive to checkpoint inhibitors. Further, this case demonstrates clearly the phenomenon of pseudo-progression in this disease, a factor that must be considered in the design of clinical trials and clinical care. This case supports additional study of immunomodulatory agents in this deadly disease.Abbreviations:CTACancer testis antigenNGSNextGen sequencing